HOPE-HF: Home Monitoring in Pediatric Heart Failure

Sponsor
Bambino Gesù Hospital and Research Institute (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05017077
Collaborator
(none)
20
1
1
19
1.1

Study Details

Study Description

Brief Summary

Heart failure is a complex clinical syndrome, representing the final evolution of many cardiac diseases that may differ for etiology and pathophysiology. In pediatric population, it is particularly challenging to manage because of the heterogeneity in age, primary cardiac disease, and the broad range of clinical signs and symptoms. Frequent hospitalizations are current problem. Hospitalization within the first year since the first episode, lack of adherence to medical therapy and diet difficulties are the main issues in this population of patients, and they rebounds on prognosis and public health costs. Actions aimed to prevent and manage these matters will improve outcome in patients with chronic heart failure. Telemedicine proved its usefulness in adult population, but, nowadays, no studies have been conducted in children. From the beginning of 21th century, remote monitoring attempts have been adopted, initially by phone calls. Currently, the e-care monitoring fits in the context of telemedicine 2.0 based on new communication models. The aim of this study is to affirm the feasibility and efficacy of a new model of tele monitoring in pediatric population. High-risk patients need a strict clinical control normally difficult to adopt. A telematics system capable to detect vital parameters as heart rate, body temperature, blood pressure, oxygen saturation, breathe frequency, weight, arrhythmias and cardiac index may offers to physician valuable information able to strictly monitoring the clinical status of patients. All of these data permits to physician to early detect critical signals of a deteriorated status, modify adherence to care and implement therapeutic strategies in order to prevent frequent hospitalizations. Our project provides a system of continuous tele-monitoring of vital parameters through a patch applied on the chest of the baby. Data are sent to a service center, "virtual clinic" and daily analyzed in multiparametric system by a specialized nurse. On the basis of pre-established alarms, the virtual clinic will notify to physician. Feasibility and tolerability of this new monitoring system will be evaluated after a 3 months period on a cohort of 20 patients affected by chronic, high-risk, heart failure.

Condition or Disease Intervention/Treatment Phase
  • Device: DynaVision System
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Home Telemonitoring in Pediatric Heart Failure
Anticipated Study Start Date :
Sep 1, 2021
Anticipated Primary Completion Date :
Apr 1, 2022
Anticipated Study Completion Date :
Apr 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Telemonitoring

To evaluate the feasibility and efficacy of a new model of tele monitoring in pediatric population in advanced heart failure, we will enroll 20 patients in advanced NYHA/Ross class in waiting list for Heart Transplant. An home telemonitoring capable to detect vital parameters as heart rate, body temperature, blood pressure, oxygen saturation, breathe frequency, weight, arrhythmias and cardiac index may offers to physician valuable information able to strictly monitoring the clinical status of patients

Device: DynaVision System
Telemonitoring for pediatric heart failure

Outcome Measures

Primary Outcome Measures

  1. Primary outcome [three months]

    number of day (percentage) of adherence to telemonitoring, at least 18 hours per day when the patient kept the patch applied at 3 months.

Secondary Outcome Measures

  1. Number of hours of patch kept applied [at 1 week]

    Tolerability

  2. Number of hours of patch kept applied [at 3 months]

    Tolerability

  3. Interquartile Range - median of hours of patch kept applied [at 1 week]

    Tolerability

  4. Interquartile Range - median of hours of patch kept applied [at 3 months]

    Tolerability

  5. Number of unplanned hospitalization [3 months]

    Reliability

  6. Number of life treating arrhythmias [3 months]

    Reliability

  7. Mortality [3 months]

    Reliability

  8. Number of unplanned hospital access (day hospital / ambulatory) [3 months]

    Reliability

  9. Comparison to levels of Hemoglobin (g/dL) [3 months]

    Reliability

  10. Comparison to levels of Albumin (g/dL) [3 months]

    Reliability

  11. Comparison to levels of Sodium (mEq/L) [3 months]

    Reliability

  12. Comparison to levels of Potassium (mEq/L) [3 months]

    Reliability

  13. Comparison to levels of Serum Creatinine (mg/dL) [3 months]

    Reliability

  14. Satisfaction questionnaire [1 week]

    Satisfaction

  15. Satisfaction questionnaire [3 months]

    Satisfaction

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Month to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • NYHA/Ross class III or IV

  • Severe impairment of ventricular function (EF < 40%) both for left or univentricular

  • Prior hospitalization for acute heart failure within 1 year

  • At least 2 prior hospitalization for acute heart failure

  • Patients on waiting list for orthotopic heart transplantation (UNOS 1B,2)

  • Informed consent obtained

Exclusion Criteria:
  • PMK or ICD

  • hospitalized patients

  • neurological or psychiatric impairment

  • urgent waiting list for heart transplantation (UNOS 1A)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Bambino Gesù Hospital Rome Italy 00165

Sponsors and Collaborators

  • Bambino Gesù Hospital and Research Institute

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Rachele Adorisio, Principal Investigator, Bambino Gesù Hospital and Research Institute
ClinicalTrials.gov Identifier:
NCT05017077
Other Study ID Numbers:
  • 2240_OPBG_2020
First Posted:
Aug 23, 2021
Last Update Posted:
Aug 23, 2021
Last Verified:
Aug 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 23, 2021